The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
about
Evaluation of Physical Properties of Generic and Branded Travoprost FormulationsPotential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literatureA randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic)Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic reviewNear real-time adverse drug reaction surveillance within population-based health networks: methodology considerations for data accrual.A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance lossUnderstanding patients' perspective in the use of generic antiepileptic drugs: compelling lessons for physicians to improve physician/patient communication.Potential Clinical and Economic Impact of Switching Branded Medications to Generics.Study on requirements of bioequivalence for registration of pharmaceutical products in USA, Europe and CanadaPay for performance (P4P) in medical imaging: the time has (finally) come.Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?Distribution and trends in outpatient utilization of generic versus brand name psychopharmaceuticals during a ten-year period in Croatia.Pharmaceutical quality of seven generic Levodopa/Benserazide products compared with original Madopar® / Prolopa®.Clinical experience with generic levetiracetam in people with epilepsy.Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective StudyPharmacy switch of antipsychotic medications: patient's perspective.Exploring factors underlying the attitude of community pharmacists to generic substitution: a nationwide study from Poland.The introduction of generic risperidone in Medicare Part DEfficacy of Generic Granisetron vs Kytril® for PONV in Major Gynecological Operations: A Randomized, Double-blind Clinical TrialThree-way, three-period, crossover bioequivalence study of single oral dose of three brands of 300 mg phenytoin sodium tablets marketed in India, on healthy Indian human volunteersThe economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.Paroxetine mesylate: comparable to paroxetine hydrochloride?Generic substitution of antiepileptic drugs.Switching from brand-name to generic psychotropic medications: a literature review.Requirements for generic antiepileptic medicines: a clinical perspective.An accurate and precise representation of drug ingredients.Nonbioequivalent prescription drug interchangeability, concerns on patient safety and drug market dynamics in Brazil.A comparison of the intrasubject variation in drug exposure between generic and brand-name drugs: a retrospective analysis of replicate design trials.Knowledge, attitudes, and practices of community pharmacists on generic medicines in Qatar.Sex differences in the pharmacokinetics and bioequivalence of the delayed-release combination of doxylamine succinate-pyridoxine hydrochloride; implications for pharmacotherapy in pregnancy.Comparison in purity and antitumor effect of brand and generic paclitaxel against human ovarian cancer cells by an in vitro experimental model.The prescribing of generic medicines in Nigeria: knowledge, perceptions and attitudes of physicians.The complex legal and ethical issues related to generic medications. Viral hepatitis: a case studyPatients' concern about their medicine after a generic switch: a combined cross-sectional questionnaire and register study.Interchangeability of gabapentin generic formulations in the Netherlands: a comparative bioavailability study.Bioequivalence study of four different trademarks of enalapril maleate in spontaneously hypertensive rats.Efficacy and safety of brand-risperidone versus similar-risperidone in elderly patients with neuropsychiatric disorders: A retrospective study.Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs.Methodological Considerations for Comparison of Brand Versus Generic Versus Authorized Generic Adverse Event Reports in the US Food and Drug Administration Adverse Event Reporting System (FAERS).
P2860
Q26741012-B21E9592-FF4D-45B2-9258-9D57BEB2A5DFQ26749431-097B4295-A1B1-48A3-BE08-BDD6EBDA609AQ26779556-2D149A83-156D-424C-A70B-EE930A37685BQ26824973-C19E9BD5-C29A-4F82-B0C1-5B8525012EE9Q30588232-4AE9C595-B346-42B5-9CF9-B15E23EA186CQ33410397-56EFC9FE-1691-4F3E-AA9A-C42208117489Q33418937-10398D3D-40D0-4ACF-AC75-81BC39D33285Q33637817-D4FB17EE-6A61-423A-A104-FBBAB1FC97ADQ34581511-5E2073A2-F3EF-4FE8-B8B1-066C4D6877A9Q34607077-56F70B05-4EEC-4A30-98AF-DAB95E18B317Q34614739-1FA45B92-5570-453B-86B4-B009466FAA64Q34669292-8F8ACAEA-28C2-4883-AAF8-C3E7C0C4C831Q34687382-D07D3CB1-A758-4BC5-8BF3-DC2D2080F28EQ35845438-B8723A45-5954-4C0D-9710-993CE935744CQ35965576-8A504F3B-7465-47B5-A422-C46F213E837CQ36093400-65D3FE5D-4DF7-4221-9E4B-7F8DECA5127BQ36521190-A2DE5814-B0D2-4AF1-BB24-3E093EC196CBQ37024443-8C6E3699-179F-442F-BBB0-122FE3B87891Q37268281-F8731722-DB20-400D-A1A6-1A19094B7C1DQ37303590-605278DA-11EC-455B-9613-4D1B83CF1C31Q37575533-150FB190-17F9-4875-8F5E-DC9BF9EAE898Q37678422-11FBCCC1-0934-4E83-A003-3709D3BD6EA8Q37810997-7BFE1D90-5979-4F86-9A59-9B3653BF9720Q37813190-B7B1E447-2746-4F97-B950-31CF0932E68BQ37888545-F13A2890-F9B7-4FE5-8DF9-239E6E5E4854Q38393436-E4C55C0B-7EA7-4801-8E95-E52316A3D8CBQ38632178-E5B0A563-B1FB-4300-993B-0241E47CDF51Q39221175-E2C511EA-31F6-4813-99BE-F1136E8C1CEEQ39249776-7EFBBBF2-BCC4-4AAE-8499-46B229B0CB1BQ39333369-104442D3-1391-45F7-8A57-9CE9E84A765DQ39659161-565935FF-4851-4763-B5E0-28076B9448B5Q40322708-C352B584-C39B-4348-BB4A-3DF4110AFB48Q42365538-9EBBEE63-991C-438C-8AD1-F87C46E4C7D2Q44772894-E9A33D85-BD21-4815-BAF0-08769E379882Q45897472-ED558067-230B-4EF9-91D6-C7C4FFEC3BFFQ46677095-0393FC6F-FAC4-4283-8AD5-2893C13EEA9FQ47137102-E1082280-E32C-4BD0-939E-1AE81FFE230FQ47381084-AAD70B48-326B-4157-A256-D35721B7EBA2Q47950620-25C9C9BC-39E0-4ECF-B0CC-C9764C0B947D
P2860
The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The bioequivalence and therape ...... brand-name psychoactive drugs.
@ast
The bioequivalence and therape ...... brand-name psychoactive drugs.
@en
The bioequivalence and therape ...... brand-name psychoactive drugs.
@nl
type
label
The bioequivalence and therape ...... brand-name psychoactive drugs.
@ast
The bioequivalence and therape ...... brand-name psychoactive drugs.
@en
The bioequivalence and therape ...... brand-name psychoactive drugs.
@nl
prefLabel
The bioequivalence and therape ...... brand-name psychoactive drugs.
@ast
The bioequivalence and therape ...... brand-name psychoactive drugs.
@en
The bioequivalence and therape ...... brand-name psychoactive drugs.
@nl
P1476
The bioequivalence and therape ...... brand-name psychoactive drugs.
@en
P2093
Giuseppe Borgheini
P304
P356
10.1016/S0149-2918(03)80157-1
P577
2003-06-01T00:00:00Z